User Tools

Site Tools


Table of Contents


see also:


  • a xanthine oxidase inhibitor introduced in 2015, as a new Rx to lower uric acid levels in patients with chronic tophaceous gout
  • trials suggest it may be more effective than allopurinol but does risk cessation due to causing abnormal LFTs, and commencement needs to be covered with non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine for 6 months as flare ups at commencement are more likely.
  • other side effects appear to be similar to those of allopurinol

drug interactions


  • for patients with tophi, start at 40mg/d, if urate levels > 0.36mM after 2-4wks Rx, then increase to 80mg/d
  • trials have used doses up to 240mg/d but effectiveness was little better than 120mg/d and presumably had greater adverse effects
  • no dose reduction is needed if creatinine clearance > 30 mL/min and liver function is not severely impaired
febuxostat.txt · Last modified: 2015/10/04 13:16 by

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki